

## Order information

REF	CONTENT	Analyzer(s) on which <b>cobas c</b> pack(s) can be used
03038866 322	LDL-Cholesterol plus 2nd generation 175 tests	System-ID 07 6627 5 Roche/Hitachi <b>cobas c</b> 311, <b>cobas c</b> 501/502
12172623 122	Calibrator f.a.s. Lipids (3 x 1 mL)	Code 424
12172623 160	Calibrator f.a.s. Lipids (3 x 1 mL, for USA)	Code 424
10781827 122	Precinorm L (4 x 3 mL)	Code 304
11778552 122	Precipath HDL/LDL-C (4 x 3 mL)	Code 319
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

## English

## System information

For **cobas c** 311/501 analyzers:

**LDL\_C**: ACN 059

For **cobas c** 502 analyzer:

**LDL\_C**: ACN 8059

## Intended use

In vitro test for the quantitative determination of LDL-cholesterol in human serum and plasma on Roche/Hitachi **cobas c** systems.

## Summary

Low Density Lipoproteins (LDL) play a key role in causing and influencing the progression of atherosclerosis and, in particular, coronary sclerosis. The LDLs are derived from VLDLs (Very Low Density Lipoproteins) rich in triglycerides by the action of various lipolytic enzymes and are synthesized in the liver. The elimination of LDL from plasma takes place mainly by liver parenchymal cells via specific LDL receptors. Elevated LDL concentrations in blood and an increase in their residence time coupled with an increase in the biological modification rate results in the destruction of the endothelial function and a higher LDL-cholesterol uptake in the monocyte/macrophage system as well as by smooth muscle cells in vessel walls. The majority of cholesterol stored in atherosclerotic plaques originates from LDL. The LDL-cholesterol value is the most powerful clinical predictor among all of the single parameters with respect to coronary atherosclerosis. Therefore, therapies focusing on lipid reduction primarily target the reduction of LDL-cholesterol which is then expressed in an improvement of the endothelial function, prevention of atherosclerosis and reducing its progression as well as preventing plaque rupture.

Various methods are available for the determination of LDL-cholesterol such as ultracentrifugation as the reference method, lipoprotein electrophoresis and precipitation methods. In the precipitation methods apolipoprotein B-containing LDL-cholesterol is, for example, precipitated using either polyvinyl sulfate, dextran sulfate or polycyclic anions. The LDL-cholesterol content is usually calculated from the difference between total cholesterol and cholesterol in the remainder (VLDL- and HDL-cholesterol) in the supernate after precipitation with polyvinyl sulfate and dextran sulfate. Lipid Research Clinics recommend a combination of ultracentrifugation and precipitation methods using polyanions in the presence of divalent cations. The precipitation methods are, however, time-consuming, cannot be automated and are susceptible to interference by hyperlipidemic serum, particularly at high concentrations of free fatty acids. A more recent method is based on the determination of LDL-cholesterol after the sample is subjected to immunoabsorption and centrifugation.

The calculation of the LDL-cholesterol concentration according to Friedewald's formula is commonly practised. The formula is based on 2 cholesterol determinations, 1 triglyceride determination as well as precipitation of the HDL particles and presumes that a direct relationship exists between VLDL-cholesterol and triglycerides in fasting blood samples. Even in the presence of small amounts of chylomicrons or abnormal lipoproteins, the formula gives rise to artificially low LDL-cholesterol values. For this reason, there is a great need for a simple and reliable method for


the determination of LDL-cholesterol without any preparatory steps or calculation.

This automated method for the direct determination of LDL-cholesterol takes advantage of the selective micellar solubilization of LDL-cholesterol by a nonionic detergent and the interaction of a sugar compound and lipoproteins (VLDL and chylomicrons). When a detergent is included in the enzymatic method for cholesterol determination (cholesterol esterase, cholesterol oxidase coupling reaction), the relative reactivities of cholesterol in the lipoprotein fractions increase in this order: HDL < chylomicrons < VLDL < LDL. In the presence of Mg<sup>++</sup>, a sugar compound markedly reduces the enzymatic reaction of the cholesterol measurement in VLDL and chylomicrons. The combination of a sugar compound with detergent enables the selective determination of LDL-cholesterol in serum.<sup>1,2,3,4,5,6,7,8</sup>


Non-fasting sample results are slightly lower than fasting results. Comparable non-fasting results were observed with the beta quantification method.<sup>9,10,11</sup> This direct assay meets the 1995 NCEP goals of < 4 % total CV, bias ≤ 4 % versus reference method, and ≤ 12 % total analytical error.<sup>12</sup>

## Test principle


Homogeneous enzymatic colorimetric assay.



Cholesterol esters are broken down quantitatively into free cholesterol and fatty acids by cholesterol esterase.



In the presence of oxygen, cholesterol is oxidized by cholesterol oxidase to Δ<sup>4</sup>-cholestenone and hydrogen peroxide.



a) HSDA = Sodium N-(2-hydroxy-3-sulfo-propyl)-3,5-dimethoxyaniline

In the presence of peroxidase, the hydrogen peroxide generated reacts with 4-aminoantipyrine and HSDA to form a purple-blue dye. The color intensity of this dye is directly proportional to the cholesterol concentration and is measured photometrically.

**Reagents - working solutions**

- R1** MOPS (3-morpholinopropane sulfonic acid) buffer: 20.1 mmol/L, pH 6.5; HSDA: 0.96 mmol/L; ascorbate oxidase (Eupenicillium spec., recombinant):  $\geq 50 \mu\text{kat/L}$ ; peroxidase (horseradish):  $\geq 167 \mu\text{kat/L}$ ; preservative
- R2** MOPS (3-morpholinopropane sulfonic acid) buffer: 20.1 mmol/L, pH 6.8;  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ : 8.11 mmol/L; 4-aminoantipyrine: 2.46 mmol/L; cholesterol esterase (Pseudomonas spec.):  $\geq 50 \mu\text{kat/L}$ ; cholesterol oxidase (Brevibacterium spec., recombinant):  $\geq 33.3 \mu\text{kat/L}$ ; peroxidase (horseradish):  $\geq 334 \mu\text{kat/L}$ ; detergent; preservative

R1 is in position B and R2 is in position C.

**Precautions and warnings**

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: For prescription use only.

**Reagent handling**

Ready for use

**Storage and stability***LDL\_C*

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

*Diluent NaCl 9 %*

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

**Specimen collection and preparation**

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum.

Plasma: Li-heparin plasma

EDTA plasma causes decreased values.

Fasting and non-fasting samples can be used.<sup>10</sup>

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability:<sup>11</sup> 7 days at 2-8 °C  
30 days at (-60)-(-80) °C

It is reported that EDTA stabilizes lipoproteins.<sup>12</sup>

**Materials provided**

See "Reagents – working solutions" section for reagents.

**Materials required (but not provided)**

- See "Order information" section
- General laboratory equipment

**Assay**

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

**Application for serum and plasma****cobas c 311 test definition**

Assay type	2-Point End	
Reaction time / Assay points	10 / 6-31	
Wavelength (sub/main)	700/600 nm	
Reaction direction	Increase	
Units	mmol/L (mg/dL, g/L)	
Reagent pipetting	Diluent (H <sub>2</sub> O)	
R1	150 $\mu\text{L}$	–
R2	50 $\mu\text{L}$	–

<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2 $\mu\text{L}$	–	–
Decreased	10 $\mu\text{L}$	15 $\mu\text{L}$	135 $\mu\text{L}$
Increased	2 $\mu\text{L}$	–	–

**cobas c 501 test definition**

Assay type	2-Point End	
Reaction time / Assay points	10 / 10-47	
Wavelength (sub/main)	700/600 nm	
Reaction direction	Increase	
Units	mmol/L (mg/dL, g/L)	
Reagent pipetting	Diluent (H <sub>2</sub> O)	
R1	150 $\mu\text{L}$	–
R2	50 $\mu\text{L}$	–

<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2 $\mu\text{L}$	–	–
Decreased	10 $\mu\text{L}$	15 $\mu\text{L}$	135 $\mu\text{L}$
Increased	2 $\mu\text{L}$	–	–

**cobas c 502 test definition**

Assay type	2-Point End	
Reaction time / Assay points	10 / 10-47	
Wavelength (sub/main)	700/600 nm	
Reaction direction	Increase	
Units	mmol/L (mg/dL, g/L)	
Reagent pipetting	Diluent (H <sub>2</sub> O)	
R1	150 $\mu\text{L}$	–
R2	50 $\mu\text{L}$	–

<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	2 $\mu\text{L}$	–	–

Decreased	10 µL	15 µL	135 µL
Increased	4 µL	–	–

**Calibration**

Calibrators	S1: H <sub>2</sub> O S2: C.f.a.s. Lipids
Calibration mode	Linear
Calibration frequency	2-point calibration <ul style="list-style-type: none"> <li>• after reagent lot change</li> <li>• as required following quality control procedures</li> </ul>

Traceability: This method has been standardized against the beta quantification method as defined in the recommendations in the LDL Cholesterol Method Certification Protocol for Manufacturers.<sup>13</sup>

**Quality control**

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

**Calculation**

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	mmol/L x 38.66 = mg/dL
	mmol/L x 0.3866 = g/L
	mg/dL x 0.0259 = mmol/L

**Limitations – interference**

Criterion: Recovery within ± 10 % of initial values at LDL cholesterol levels of 4.0 mmol/L (154 mg/dL).

Icterus:<sup>14</sup> No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:<sup>14</sup> No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):<sup>14</sup> No significant interference up to an L index of 200.

There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

No significant interference from HDL (≤ 75 mg/dL), VLDL (≤ 140 mg/dL), or chylomicrons (≤ 2000 mg/dL triglycerides).

Drugs: No interference was found at therapeutic concentrations using common drug panels.<sup>15,16</sup>

Exception: Intralipid causes artificially high LDL cholesterol results.

Ascorbic acid up to 50 mg/dL (2.84 mmol/L) does not interfere.

Abnormal liver function affects lipid metabolism; consequently HDL and LDL results are of limited diagnostic value. In some patients with abnormal liver function, the LDL-cholesterol result is significantly negatively biased versus beta quantification results.

Acetaminophen intoxications are frequently treated with N-Acetylcysteine. N-Acetylcysteine at the therapeutic concentration when used as an antidote and the Acetaminophen metabolite N-acetyl-p-benzoquinone imine (NAPQI) independently may cause falsely low results.

Venipuncture should be performed prior to the administration of Metamizole. Venipuncture immediately after or during the administration of Metamizole may lead to falsely low results.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.<sup>17</sup>

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

**ACTION REQUIRED**

**Special Wash Programming:** The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCin1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

**Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.**

**Limits and ranges****Measuring range**

0.10-14.2 mmol/L (3.86-548 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

**Lower limits of measurement***Lower detection limit of the test*

0.10 mmol/L (3.86 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

**Expected values<sup>18</sup>**

Levels in terms of risk for coronary heart disease:

Adult levels:

Optimal	< 2.59 mmol/L (< 100 mg/dL)
Near optimal/above optimal	2.59-3.34 mmol/L (100-129 mg/dL)
Borderline high	3.37-4.12 mmol/L (130-159 mg/dL)
High	4.14-4.89 mmol/L (160-189 mg/dL)
Very high	≥ 4.92 mmol/L (≥ 190 mg/dL)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

**Specific performance data**

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

**Precision**

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L (mg/dL)</i>	<i>mmol/L (mg/dL)</i>	<i>%</i>
Precinorm L	2.78 (107)	0.02 (1)	0.7
Precipath HDL/LDL-C	5.50 (212)	0.04 (2)	0.8
Human serum 1	2.51 (96.9)	0.02 (0.8)	0.9
Human serum 2	6.14 (237)	0.08 (3)	1.3
<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>mmol/L (mg/dL)</i>	<i>mmol/L (mg/dL)</i>	<i>%</i>
Precinorm L	2.65 (102)	0.07 (3)	2.7
Precipath HDL/LDL-C	5.42 (209)	0.12 (5)	2.3
Human serum 3	1.47 (56.8)	0.03 (1.2)	1.9
Human serum 4	3.95 (153)	0.08 (3)	2.1

**Method comparison**

LDL cholesterol values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c 501** analyzer (y) were compared to those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x).

Sample size (n) = 171

Passing/Bablok <sup>19</sup>	Linear regression
$y = 0.973x + 0.143$ mmol/L	$y = 0.993x + 0.089$ mmol/L
$\tau = 0.940$	$r = 0.997$

The sample concentrations were between 1.26 and 12.8 mmol/L (48.6 and 494 mg/dL).

**References**

- Rifai N, Warnick GR, McNamara JR, et al. Measurement of Low-Density-Lipoprotein Cholesterol in Serum: a Status Report. *Clin Chem* 1992;38:150-160.
- Bachoric P. Measurement of Low-Density-Lipoprotein. 245-263. In: *Handbook of Lipoprotein Testing* (eds. Rifai, Warnick and Dominiczak), 2 edition, AACCPress, 2000.
- National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). NIH Publication No. 93-3095 1995.
- Naito HK, Strong JP, Scott MG, et al. Atherogenesis: current topics on etiology and risk factors. *Clin Chem* 1995;41:132-133.
- Wieland H, Seidel D. Quantitative Lipoprotein Electrophoresis. In: *Handbook of Electrophoresis, Vol III*, ed. Lewis A, Boca Raton: CRC Press 1983;83-102.
- Armstrong V, Seidel D. Evaluation of a Commercial Kit for the Determination of LDL-Cholesterol in Serum Based on Precipitation of LDL with Dextran Sulfate. *Ärztl Lab* 1985;31:325-330.
- Friedewald WF, Levy RI, Frederickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. *Clin Chem* 1972;18(6):499-502.
- Bachoric PS, Ross JW. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. *Clin Chem* 1995;41:1414-1420.
- Cohn JS, McNamara JR, Schaefer EJ. Lipoprotein Cholesterol Concentrations in the Plasma of Human Subjects as Measured in the Fed and Fasted States. *Clin Chem* 1988;34:2456-2459.
- Pisani T, Gebiski CP, Leary ET, et al. Accurate Direct Determination of Low-density Lipoprotein Cholesterol Using an Immunoseparation Reagent and Enzymatic Cholesterol Assay. *Arch Pathol Lab Med* 1995 Dec;119(12):1127-1135.
- Data on file at Roche Diagnostics.
- Cooper GR, Myers GL, Smith SJ, et al. Standardization of Lipid, Lipoprotein, and Apolipoprotein Measurements. *Clin Chem* 1988;34(8B):B95-B105.
- LDL Cholesterol Method Certification Protocol for Manufacturers. National Reference System for Cholesterol. Cholesterol Reference Method Laboratory Network 1997, October.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. *Clin Chem* 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". *Eur J Clin Chem Clin Biochem* 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. *Ann Clin Biochem* 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. *Clin Chem Lab Med* 2007;45(9):1240-1243.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No 01-3670; May 2001.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

**Symbols**

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard.

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

**FOR US CUSTOMERS ONLY: LIMITED WARRANTY**

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, PRECICONTROL, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2015, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
www.roche.com

Distribution in USA by:  
Roche Diagnostics, Indianapolis, IN  
US Customer Technical Support 1-800-428-2336

